In a more comprehensive investigation, the activity of PC, FII, FX, FXI and FXII, and propensity of fibrinogen to clot was determined in plasma samples of MS patients with different clinical phenotypes compared to healthy individuals (136). This evidence concerns the gene F11 and myeloid sarcoma.